In 2018, the FDA approved Epidiolex, the first ever cannabis-based oral medication for the treatment of two rare and severe seizure disorders. Clinical trials showed it decreased seizure activity by an average of 45% to 50% in patients with Dravet syndrome, a rare and severe form of childhood-onset epilepsy.
